WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca ...
AstraZeneca has rolled out a fresh TV spot for its blockbuster-to-be Breztri, hitting the message that the product frees chronic obstructive pulmonary disease (COPD) patients to leave their bad days ...
Glaucoma and cataracts may occur with long-term use of ICS. Worsening of narrow-angle glaucoma may occur, so use with caution. Consider referral to an ophthalmologist in patients who develop ocular ...
THARROS is the first-ever prospective trial to investigate the potential of an inhaled triple therapy to reduce cardiopulmonary events, a key driver of mortality, in COPD First patients dosed in ...
On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials ...
The main outcome of the phase 3 THARROS trial will be to assess the efficacy of Breztri Aerosphere on reducing severe cardiopulmonary events in COPD patients who are at increased cardiopulmonary risk.
Breztri can cost $400 or more without insurance, but Medicare may cover inhaler drugs for COPD, including Breztri. That said, the specific coverage and costs vary based on your exact plan. Breztri ...
Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRIin patients with uncontrolled asthma published in The Lancet Respiratory Medicine Full results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results